Sasi Kumar Kotagiri

About

I did my undergraduation with Genetics as my major. Later, I worked as graduate student in Dr. V.Radha Lab at Center for cellular and Molecular Biology and got my Ph.D degree in life sciences from Jawaharlal nehru university, one of the prestigious institues of INDIA. During my graduation I worked on chronic myeloid leukemia and skeletal muscle differentiation. As a postdoctoral fellow in Dr. Srigiridhar Kotamraju Lab, I worked on drug discovery for diabetes in Indian Institute of Chemical Biology, Hyderabd, INDIA. Currently, working as a postdoctoral fellow in Dr. Lissanu Lab at MD Anderson Cancer Center, Houston, Texas. My research interest is drug discovery for lung cancer. My goal is to understand the molecular mechanisms that cause cancer and seek more effective therapeutic interventions.

Employment

• MD anderson cancer center Postdoctoral fellow
  2020 - 2025

Education

• Centre for Cellular and Molecular Biology Ph.D
  2009 - 2017
• Osmania University UNDERGRADUATION
  2005 - 2007

Projects & Funding

Projects & funding information is unavailable.

Publications (10)

• Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors
  Journal of Medicinal Chemistry 2025 DOI: 10.1021/acs.jmedchem.4c02577
  +Save
• Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy
  Cancer Research 2025 DOI: 10.1158/0008-5472.CAN-24-2054
  +Save
• Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors
  Biorxiv 2024 DOI: 10.1101/2024.08.23.608456
  +Save
• Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer
  Cell Chemical Biology 2024 DOI: 10.1016/j.chembiol.2024.09.004
  +Save
• SMARCA4 mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy
  Biorxiv 2024 DOI: 10.1101/2024.06.18.599431
  +Save
• Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: Relevance in age-associated vascular dysfunction.
  Biochimica et biophysica acta. Molecular basis of disease 2018 DOI: 10.1016/j.bbadis.2018.01.018
  +Save
• C3G (RapGEF1), a regulator of actin dynamics promotes survival and myogenic differentiation of mouse mesenchymal cells.
  Biochimica et biophysica acta 2015 DOI: 10.1016/j.bbamcr.2015.06.015
  +Save
• The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.
  Biochimica et biophysica acta 2012 DOI: 10.1016/j.bbadis.2012.10.014
  +Save
• Reciprocal Negative Regulation between the Guanine Nucleotide Exchange Factor C3G and β-Catenin.
  Genes & cancer 2012 DOI: 10.1177/1947601912471189
  +Save
• Signalling to actin: role of C3G, a multitasking guanine-nucleotide-exchange factor.
  Bioscience reports 2011 DOI: 10.1042/bsr20100094
  +Save